{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:01:04Z","timestamp":1790204464709,"version":"4.1.0"},"reference-count":72,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die metabolische Dysfunktion-assoziierte steatotische Lebererkrankung (MASLD) ist eine progrediente Lebererkrankung, gekennzeichnet durch Entz\u00fcndung, Fibrose und metabolische Dysfunktion. In den letzten Jahren haben sich die Behandlungsm\u00f6glichkeiten deutlich erweitert. Der Schilddr\u00fcsenhormon-Rezeptor-\u03b2-Agonist Resmetirom wurde 2025 als erster Wirkstoff in Deutschland f\u00fcr die nicht-zirrhotische MASH mit moderater bis fortgeschrittener Fibrose zugelassen. Zudem werden Inkretin-Analoga, urspr\u00fcnglich f\u00fcr Diabetes und \u00dcbergewicht entwickelt, untersucht. In einer Phase-3-Studie zeigte Semaglutid signifikante Verbesserungen von Entz\u00fcndung und Fibrose. Neben den GLP-1-Analoga, die indirekt \u00fcber den Stoffwechsel wirken, gibt es Leberfibrose-spezifische Therapien wie FGF-21-Analoga und duale Inkretin-Analoga (z.B. Survodutid), die \u00fcber den Glukagon-Rezeptor Leberzellen direkt beeinflussen. Auch Kombinationstherapien werden f\u00fcr synergistische Effekte und eine individualisierte Behandlung zunehmend untersucht. Laufende Phase-3-Studien pr\u00fcfen Langzeitwirksamkeit und Sicherheit. Parallel werden Biomarker zur Patientenselektion und Therapiekontrolle entwickelt. Das deutsche SLD-Register wird Patientendaten und Verl\u00e4ufe nach der Zulassung neuer Therapien erfassen. In diesem Review fassen wir aktuelle Entwicklungen und Ausblicke zur medikament\u00f6sen Therapie bei MASH zusammen. Die Kombination aus metabolischer und leberspezifischer Therapie bietet gro\u00dfes Potenzial f\u00fcr eine personalisierte Medizin.<\/jats:p>","DOI":"10.1055\/a-2894-7716","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:31:01Z","timestamp":1790202661000},"page":"1250-1260","source":"Crossref","is-referenced-by-count":0,"title":["Neue Therapieans\u00e4tze bei MASH: Mechanismen und klinisches Potenzial"],"prefix":"10.1055","volume":"64","author":[{"given":"Alexander","family":"Barton","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum des Saarlandes, Deutschland","place":["Homburg"],"department":["Klinik f\u00fcr Innere Medizin II (Gastroenterologie, Hepatologie, Endokrinologie, Diabetologie und Ern\u00e4hrungsmedizin)"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum des Saarlandes, Deutschland","place":["Homburg"],"department":["Klinik f\u00fcr Innere Medizin II (Gastroenterologie, Hepatologie, Endokrinologie, Diabetologie und Ern\u00e4hrungsmedizin)"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"ZM Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"ME Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/CMH.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"ZM Younossi","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/J.JHEP.2024.04.031\/ASSET\/E92E5B46-7955-4358-85EC-34B4A3822047\/MAIN.ASSETS\/GR2.JPG","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"F Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/J.CELL.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"R Loomba","year":"2021","journal-title":"Cell"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/HEP.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"PS Dulai","year":"2017","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"RS Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMOA2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"SA Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMOA2413258\/SUPPL_FILE\/NEJMOA2413258_DATA-SHARING.PDF","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction\u2013Associated Steatohepatitis","volume":"392","author":"AJ Sanyal","year":"2025","journal-title":"New England Journal of Medicine"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/J.CMET.2024.03.011\/ASSET\/8EBEAAD8-4B5A-4A3D-84F8-A0005740D496\/MAIN.ASSETS\/GR1_LRG.JPG","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"MA Tincopa","year":"2024","journal-title":"Cell Metab"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3350\/CMH.2025.0083","article-title":"Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment","volume":"31","author":"HY Kim","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction\u2013associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis","volume":"82","author":"M Souza","year":"2025","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/J.METABOL.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"E Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHARMR.2024.100018\/ASSET\/15416E50-83AC-4429-A866-E1F1DED28532\/MAIN.ASSETS\/GR3.JPG","article-title":"Pharmacological treatment for metabolic dysfunction\u2013associated steatotic liver disease and related disorders: Current and emerging therapeutic options","volume":"77","author":"X Zhang","year":"2025","journal-title":"Pharmacol Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/S41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"SL Friedman","year":"2018","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/J.BBALIP.2009.10.007","article-title":"Fatty liver and lipotoxicity","volume":"1801","author":"M Trauner","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/METABO12030238","article-title":"Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH","volume":"12","author":"RD Welch","year":"2022","journal-title":"Metabolites"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/J.AOHEP.2025.101777","article-title":"From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"M Zhou","year":"2025","journal-title":"Ann Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/J.JHEP.2020.04.003\/ATTACHMENT\/DC984D5C-4BE8-47E8-B445-57B6C5130320\/MMC3.PDF","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort\u2606","volume":"73","author":"QM Anstee","year":"2020","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1053\/J.GASTRO.2023.01.040","article-title":"PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis","volume":"164","author":"VL Chen","year":"2023","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEPR.2026.101798","article-title":"Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management\u2606","volume":"101798","author":"BW Pieter","year":"2026","journal-title":"JHEP Reports"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/J.GASTRO.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"E Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/J.JHEP.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"VWS Wong","year":"2018","journal-title":"J Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1055\/S-0041-1723751","article-title":"Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials","volume":"41","author":"T Kawaguchi","year":"2021","journal-title":"Semin Liver Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/S12876-025-04535-1","article-title":"Comparative efficacy of different diet modalities on metabolic profiles and liver functions in metabolic dysfunction-associated fatty liver disease: a network meta-analysis","volume":"26","author":"J Zou","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.14309\/AJG.0000000000002098","article-title":"Exercise Training Is Associated With Treatment Response in Liver Fat Content by Magnetic Resonance Imaging Independent of Clinically Significant Body Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"118","author":"JG Stine","year":"2023","journal-title":"American Journal of Gastroenterology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.14309\/AJG.0000000000002222","article-title":"Significant Dose-Response Association of Physical Activity and Diet Quality with Mortality in Adults with Suspected NAFLD in a Population Study","volume":"118","author":"E Vilar-Gomez","year":"2023","journal-title":"American Journal of Gastroenterology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/HEP.28992\/SUPPINFO","article-title":"Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study","volume":"65","author":"A Berzigotti","year":"2017","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/JCSM.12039","article-title":"Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis","volume":"7","author":"AJ Montano-Loza","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/J.JHEP.2018.06.024","article-title":"EASL Clinical Practice Guidelines on nutrition in chronic liver disease","volume":"70","author":"M Merli","year":"2018","journal-title":"J Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"ME Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMOA2029349","article-title":"Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease","volume":"385","author":"AJ Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"14605","DOI":"10.3390\/IJMS241914605","article-title":"Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease","volume":"24","author":"P Vidal-Cevallos","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1089\/THY.2018.0664","article-title":"Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists","volume":"29","author":"RA Sinha","year":"2019","journal-title":"Thyroid"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/J.CGH.2024.07.003","article-title":"Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH\/NASH and Moderate to Noncirrhotic Advanced Fibrosis","volume":"22","author":"M Noureddin","year":"2024","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","volume":"81","author":"VL Chen","year":"2025","journal-title":"Hepatology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/J.GASTRO.2025.02.044","article-title":"Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis","volume":"169","author":"ZM Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S559331","article-title":"Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH)","author":"LA Van Kleef","year":"2026","journal-title":"Drug Design, Development and Therapy"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/DOM.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update","volume":"23","author":"MA Nauck","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/CTS.13235","article-title":"Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH","volume":"15","author":"MB M\u00f8llerh\u00f8j","year":"2022","journal-title":"Clin Transl Sci"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/J.TEM.2020.02.006\/ASSET\/152946EB-194E-4ADB-89C3-4A6ADC963F32\/MAIN.ASSETS\/GR2.JPG","article-title":"How May GIP Enhance the Therapeutic Efficacy of GLP-1?","volume":"31","author":"RJ Samms","year":"2020","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMOA2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"R Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/J.JHEP.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"PN Newsome","year":"2023","journal-title":"J Hepatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMOA2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"AJ Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMOA2301972","article-title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity \u2013 A Phase 2 Trial","volume":"389","author":"AM Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"J Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"AJ Sanyal","year":"2024","journal-title":"Nature Medicine 2024 30:7"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/J.JHEP.2024.04.034\/ATTACHMENT\/5380A54C-D840-4A8B-B70B-35C03EA17219\/MMC1.PDF","article-title":"FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"SA Harrison","year":"2024","journal-title":"J Hepatol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/J.CMET.2013.04.005","article-title":"Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice","volume":"17","author":"Z Lin","year":"2013","journal-title":"Cell Metab"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/J.TAAP.2015.11.012","article-title":"Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-\u03b2\/smad2\/3 and NF-\u03baB signaling pathways","volume":"290","author":"P Xu","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"567","DOI":"10.17179\/EXCLI2020-1287","article-title":"Fibroblast Growth Factor-21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells","volume":"19","author":"YK Opoku","year":"2020","journal-title":"EXCLI J"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMOA2502242","article-title":"Efruxifermin in Compensated Liver Cirrhosis Caused by MASH","volume":"392","author":"M Noureddin","year":"2025","journal-title":"New England Journal of Medicine"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"M Noureddin","year":"2025","journal-title":"The Lancet"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMOA2304286\/SUPPL_FILE\/NEJMOA2304286_DATA-SHARING.PDF","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"R Loomba","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S0140-6736(25)02276-7","article-title":"Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"407","author":"M Noureddin","year":"2026","journal-title":"The Lancet"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMOA1607141\/SUPPL_FILE\/NEJMOA1607141_DISCLOSURES.PDF","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"SP Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMOA2307563\/SUPPL_FILE\/NEJMOA2307563_DATA-SHARING.PDF","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"AM Lincoff","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-026-04281-1","article-title":"Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial","author":"SM Meyh\u00f6fer","year":"2026","journal-title":"Nat Med"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"S Francque","year":"2020","journal-title":"Nature Reviews Gastroenterology & Hepatology 2020 18:1"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"V Dubois","year":"2017","journal-title":"J Clin Invest"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/J.JHEP.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages\u2606","volume":"73","author":"S Lefere","year":"2020","journal-title":"J Hepatol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/JAMAINTERNMED.2016.9607","article-title":"Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis","volume":"177","author":"G Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMOA2036205\/SUPPL_FILE\/NEJMOA2036205_DATA-SHARING.PDF","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"SM Francque","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"E Brown","year":"2021","journal-title":"The Lancet"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/DC18-1569","article-title":"The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients","volume":"42","author":"A Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/DC19-0641","article-title":"Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial","volume":"43","author":"S Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/DOM.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"M Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/S12325-020-01498-5\/TABLES\/5","article-title":"Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"H Taheri","year":"2020","journal-title":"Adv Ther"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/APT.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis","volume":"59","author":"SA Harrison","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/APT.17925","article-title":"Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes","volume":"59","author":"MI Elsaid","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"R Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1093\/LIFEMETA\/LOAE029","article-title":"Potential therapeutic strategies for MASH: from preclinical to clinical development","volume":"3","author":"Z Xie","year":"2024","journal-title":"Life Metabolism"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2894-7716.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:31:28Z","timestamp":1790202688000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2894-7716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":72,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2894-7716","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}